Interpreting Statistical Versus Clinically Meaningful Heterogeneity

Why Statistical and Clinical Importance Are Different

A subgroup analysis can produce a small p-value while showing a difference too slight to change care. Conversely, an estimated difference that would matter greatly to patients may be too imprecise to support a confident conclusion. Statistical evidence concerns uncertainty about an effect; clinical importance concerns whether the effect is large enough to matter in a decision. They are related, but they are not the same question.

The scale matters. A subgroup difference in relative risks can look different from a difference in absolute risks, particularly when baseline risks vary. This tutorial uses an absolute risk-reduction scale so that contrasts can be expressed as events prevented per 100 people. Conclusions are specific to that scale, outcome, follow-up period, population, and treatment strategy.

For causal interpretation, the subgroup must be defined before treatment, and the effect estimates must identify the treatment effects in the stated target subgroups. In a randomized trial, this requires valid randomization and follow-up for the estimand being reported, together with consistency, no interference, and a positive probability of each assigned treatment in each subgroup. In observational data, additional identification assumptions are needed; an adjusted association alone does not establish a causal subgroup effect. The examples below are hypothetical randomized trials with valid marginal subgroup estimates. They also assume that the reported confidence intervals use an appropriate method and are approximately normal on the absolute-risk scale.

Put Clinical Importance on a Prespecified Scale

A clinical threshold should be chosen before interpreting the results, with input appropriate to the decision: patients, clinicians, or decision-makers. It should name the outcome, time horizon, effect scale, and comparison. For instance, a threshold of 5 percentage points for a subgroup contrast means that a difference of at least 5 additional events prevented per 100 people is considered important for the specified purpose. The value is not a universal property of the treatment; it depends on the benefits, harms, alternatives, and decision at hand.

A threshold for meaningful heterogeneity is not automatically the same as a minimum worthwhile treatment effect within a subgroup. The first concerns how far apart two subgroup effects must be to matter. The second concerns whether treating a particular subgroup is worthwhile compared with not treating it. A treatment might have a worthwhile benefit in both subgroups but little clinically important heterogeneity, or it might have a large subgroup contrast even though neither subgroup’s benefit alone justifies treatment.

A conventional test of \(H_0:D=0\) asks whether the data are inconsistent with exactly equal subgroup effects under the test’s assumptions. It does not ask whether \(|D|\) exceeds \(\delta\). Thus, a statistically significant contrast can be too small to matter, and a nonsignificant contrast can remain compatible with a clinically important difference. A confidence interval makes this distinction visible by showing which contrast values remain compatible with the data and method.

Uncertainty for a Difference of Subgroup Effects

Suppose the two estimated benefits are \(\hat{B}_1\) and \(\hat{B}_0\). The estimated contrast is their difference. Its uncertainty depends not only on the precision of each subgroup estimate but also on their covariance. This matters, for example, when both estimates use shared model parameters or a common standardization procedure.

The variance identity follows by expanding the variance of a difference: \(\operatorname{Var}(X-Y)=\operatorname{Var}(X)+\operatorname{Var}(Y)-2\operatorname{Cov}(X,Y)\). If the standard error \(SE(\hat{D})\) is available and a normal approximation is appropriate, an approximate 95% confidence interval is:

The standard error must come from a method suitable for the design and estimator; it should not be obtained by ignoring covariance unless independence is justified. If many subgroups or outcomes were examined, unadjusted intervals can overstate the strength of evidence from selected results. Interpretation should reflect the prespecified analysis and any multiplicity strategy.

When Statistical Evidence Does Not Mean Clinical Importance

A large sample can estimate a very small contrast precisely. In that case, the data may provide strong evidence against exactly zero while also showing that contrasts large enough to change a clinical decision are unlikely. Conversely, a smaller study may have a point estimate exceeding the clinical threshold but a broad interval that includes much smaller effects. The threshold and interval, rather than the p-value alone, address the clinical question.

Bring Treatment Burdens Into the Decision

Benefits and burdens should be compared in a way that reflects the decision, but unlike quantities should not be subtracted as though they shared a natural unit. For example, a risk reduction in percentage points cannot simply be reduced by the number of clinic visits or the percentage experiencing a different adverse effect. Instead, treatment burden can inform a prespecified threshold, or benefits and harms can be combined using an explicit utility scale that assigns values to the outcomes.

The threshold should also match the intended action. A threshold for directing a costly treatment to one subgroup may differ from a threshold for offering treatment to an individual patient. Burdens can include adverse effects, monitoring, travel, time, financial cost, or opportunity cost. Patients may value these differently. If that variation matters, report it rather than implying that one numerical cutoff is universally correct.

Common Mistake: Comparing Subgroup P-Values

A frequent error is to declare that treatment works differently across subgroups because its effect is statistically significant in one subgroup but not statistically significant in another. That comparison is invalid: “significant” and “not significant” are not themselves a statistically significant difference. The subgroup estimates may be close, with different standard errors, or far apart with substantial uncertainty. The relevant quantity is the estimated contrast between effects, with its own standard error and interval.

A second error is to equate a nonzero contrast with a clinically important one. A small contrast can have a small p-value in a large study. Conversely, failure to reject \(H_0:D=0\) is not evidence that \(|D|<\delta\). To support that latter conclusion, the interval should be sufficiently precise to lie inside the prespecified region \((-\delta,\delta)\), using an appropriate analysis.